SCHEDULE 13D: Investment Group Discloses Significant Stake in Matinas BioPharma, Seeks Board Representation

A group of investors, including Sanitam Partners LLC, HEZBAY Holdings LLC, and Platinum Point Capital, LLC, has disclosed a significant beneficial ownership stake in Matinas BioPharma Holdings, Inc., acquired through a private placement of convertible preferred stock and warrants, with plans to seek board representation.

Summary

• A group of investors, including Sanitam Partners LLC, Adam Stern, HEZBAY Holdings LLC, Ari Kluger, Platinum Point Capital, LLC, and Brian Freifeld (the "Reporting Persons"), has filed a Schedule 13D disclosing their beneficial ownership in Matinas BioPharma Holdings, Inc.
• The Reporting Persons acquired Series C Convertible Preferred Stock and Warrants through a private placement, with an initial closing on February 13, 2025, for gross proceeds of $1.65 million to Matinas BioPharma.
• The Preferred Stock is convertible into Common Stock, and Warrants are exercisable for Common Stock, but both are subject to a collective 19.99% voting and beneficial ownership cap until shareholder approval is obtained.
• Adam Stern's total beneficial ownership, including his direct holdings and shared ownership with the group, is 1,227,575 shares, representing 24.1% of the class.
• The group, including other investors Pembroke & Partners LLC and Robert Eide, could collectively own approximately 62.4% of the outstanding Common Stock on a fully diluted basis if shareholder approval is obtained.
• The investors intend to monitor their investment, engage in discussions with management and the board, and may propose changes to capitalization, ownership structure, operations, or board representation.

Sentiment

Score: 7

Explanation: The filing indicates a significant strategic investment by a group of investors, suggesting confidence in Matinas BioPharma. The potential for substantial future ownership and board representation is positive. However, the dependency on shareholder approval for full conversion rights and the second tranche of funding introduces a degree of uncertainty, preventing a higher score.

Positives

• Significant investment of $1.65 million (initial closing) into Matinas BioPharma, with potential for an additional $1.65 million upon shareholder approval, indicating investor confidence.
• The investor group, including Sanitam Partners, HEZBAY Holdings, and Platinum Point Capital, has secured the right to nominate one director (Dr. Robin Smith) to the Board immediately.
• Potential for an additional board seat if the purchasers' collective ownership reaches 30% fully diluted after the second closing.
• The group's stated intention to monitor the investment and engage with management and the board suggests active oversight and potential for strategic improvements.

Negatives

• The full conversion of Preferred Stock and exercise of Warrants, as well as the second closing of the private placement, are contingent upon obtaining shareholder approval.
• Until shareholder approval, the voting rights and beneficial ownership of the Preferred Stock and Warrants are capped at 19.99% collectively for the group, limiting their immediate influence.
• The document does not provide specific details on the company's current financial performance or operational challenges, making a full assessment of the investment's context difficult.

Risks

• Shareholder Approval Risk: The inability to obtain shareholder approval would prevent the full conversion of Preferred Stock, exercise of Warrants, and the second $1.65 million tranche of the private placement, limiting the investors' full economic and voting rights.
• Ownership Cap Risk: Until shareholder approval, the 19.99% voting and beneficial ownership cap restricts the immediate influence and full realization of the investment's potential.
• Market Conditions: The value of the investment is subject to market, general economic, and other conditions.
• Operational Risk: The investors' plans to engage with management and propose changes imply potential operational or strategic challenges within Matinas BioPharma that they aim to address.

Future Outlook

The Reporting Persons intend to continuously monitor and evaluate their investment in Matinas BioPharma, engaging in discussions with management and the board regarding the company's business, operations, and future plans. Depending on various factors, they may acquire additional securities, propose changes to capitalization, ownership structure, operations, or board representation, or dispose of their holdings. They also plan to explore and prepare for various strategic actions to increase shareholder value.

Industry Context

This Schedule 13D filing indicates a significant strategic investment by a group of investors in Matinas BioPharma, a common occurrence in the biotechnology or pharmaceutical sector where companies often rely on private placements for capital. The investor group's intent to seek board representation and potentially influence strategic direction is typical for substantial equity holders aiming to drive value in a company.

Management Changes

Corporate Governance

Legal Proceedings

• None of the Reporting Persons have been a party to a civil or criminal proceeding related to securities laws in the past five years.

Stakeholder Impact

• Shareholders: Potential for significant dilution if all Preferred Stock and Warrants are converted/exercised, especially if Shareholder Approval is obtained, leading to the investor group owning approximately 62.4% of outstanding shares. Increased investor oversight and potential strategic changes could benefit long-term shareholder value.
• Management/Board: Increased scrutiny and potential influence from the new significant investor group, including new board representation, which could lead to shifts in strategic direction or operational focus.
• Company Operations: The additional capital from the private placement (initial $1.65M, potential $1.65M) provides funding for Matinas BioPharma's operations and future plans.

Next Steps

• Matinas BioPharma to seek Shareholder Approval for the issuance of Preferred Stock and Warrants.
• Upon Shareholder Approval, a second closing of the private placement will occur, generating an additional $1.65 million in gross proceeds for the Issuer.
• If Shareholder Approval is obtained, the Preferred Stock will become fully convertible and Warrants fully exercisable without the 19.99% cap.
• The investor group will continue to monitor their investment and may engage in discussions with management and the board.
• The investor group may acquire additional securities, propose changes to capitalization, ownership structure, operations, or board representation, or dispose of their holdings.
• The Purchasers are entitled to nominate one director (Dr. Robin Smith) to the Board immediately.
• Commencing on the date of the Second Closing, the Purchasers will be entitled to nominate one additional director if they own at least 30% of the outstanding shares on a fully diluted, as-converted basis.

Key Dates

Recommendation

Keywords

Matinas BioPharma Holdings Inc., Schedule 13D, beneficial ownership, convertible preferred stock, warrants, private placement, investor group, corporate governance, board representation, shareholder activism, equity investment